Report Detail

Request for Sample of this report

Pharma & Healthcare Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4532008
    • |
  • 23 May, 2023
    • |
  • Global
    • |
  • 104 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Severe Hypertriglyceridemia (SHTG) Therapeutics market size was valued at USD 631.8 million in 2022 and is forecast to a readjusted size of USD 1550.6 million by 2029 with a CAGR of 13.7% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Severe Hypertriglyceridemia (SHTG) is a medical condition characterized by abnormally high levels of triglycerides in the blood, which can lead to the development of cardiovascular diseases. SHTG is a serious condition that requires prompt treatment to reduce the risk of cardiovascular events such as heart attacks and strokes.
This report is a detailed and comprehensive analysis for global Severe Hypertriglyceridemia (SHTG) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Treatment Method and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Severe Hypertriglyceridemia (SHTG) Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Severe Hypertriglyceridemia (SHTG) Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Severe Hypertriglyceridemia (SHTG) Therapeutics market size and forecasts, by Treatment Method and by Application, in consumption value ($ Million), 2018-2029
Global Severe Hypertriglyceridemia (SHTG) Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Severe Hypertriglyceridemia (SHTG) Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Severe Hypertriglyceridemia (SHTG) Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V. and Amryt Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Severe Hypertriglyceridemia (SHTG) Therapeutics market is split by Treatment Method and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Treatment Method and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Treatment Method
Oral
Intravenous Injection
Market segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Market segment by players, this report covers
Ionis Pharmaceuticals
89bio, Inc.
Arrowhead Pharmaceuticals, Inc.
NorthSea Therapeutics B.V.
Amryt Pharma
Afimmune Pharmaceutical
Zucara Therapeutics
Novo Nordisk
Adocia
Pfizer Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Severe Hypertriglyceridemia (SHTG) Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Severe Hypertriglyceridemia (SHTG) Therapeutics, with revenue, gross margin and global market share of Severe Hypertriglyceridemia (SHTG) Therapeutics from 2018 to 2023.
Chapter 3, the Severe Hypertriglyceridemia (SHTG) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Treatment Method and application, with consumption value and growth rate by Treatment Method, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Severe Hypertriglyceridemia (SHTG) Therapeutics market forecast, by regions, treatment method and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Severe Hypertriglyceridemia (SHTG) Therapeutics.
Chapter 13, to describe Severe Hypertriglyceridemia (SHTG) Therapeutics research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Severe Hypertriglyceridemia (SHTG) Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Severe Hypertriglyceridemia (SHTG) Therapeutics by Treatment Method
    • 1.3.1 Overview: Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Treatment Method: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value Market Share by Treatment Method in 2022
    • 1.3.3 Oral
    • 1.3.4 Intravenous Injection
  • 1.4 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market by Application
    • 1.4.1 Overview: Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospital Pharmacy
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Online Pharmacy
  • 1.5 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size & Forecast
  • 1.6 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Region, (2018-2029)
    • 1.6.3 North America Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Ionis Pharmaceuticals
    • 2.1.1 Ionis Pharmaceuticals Details
    • 2.1.2 Ionis Pharmaceuticals Major Business
    • 2.1.3 Ionis Pharmaceuticals Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.1.4 Ionis Pharmaceuticals Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Ionis Pharmaceuticals Recent Developments and Future Plans
  • 2.2 89bio, Inc.
    • 2.2.1 89bio, Inc. Details
    • 2.2.2 89bio, Inc. Major Business
    • 2.2.3 89bio, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.2.4 89bio, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 89bio, Inc. Recent Developments and Future Plans
  • 2.3 Arrowhead Pharmaceuticals, Inc.
    • 2.3.1 Arrowhead Pharmaceuticals, Inc. Details
    • 2.3.2 Arrowhead Pharmaceuticals, Inc. Major Business
    • 2.3.3 Arrowhead Pharmaceuticals, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.3.4 Arrowhead Pharmaceuticals, Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Arrowhead Pharmaceuticals, Inc. Recent Developments and Future Plans
  • 2.4 NorthSea Therapeutics B.V.
    • 2.4.1 NorthSea Therapeutics B.V. Details
    • 2.4.2 NorthSea Therapeutics B.V. Major Business
    • 2.4.3 NorthSea Therapeutics B.V. Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.4.4 NorthSea Therapeutics B.V. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 NorthSea Therapeutics B.V. Recent Developments and Future Plans
  • 2.5 Amryt Pharma
    • 2.5.1 Amryt Pharma Details
    • 2.5.2 Amryt Pharma Major Business
    • 2.5.3 Amryt Pharma Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.5.4 Amryt Pharma Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Amryt Pharma Recent Developments and Future Plans
  • 2.6 Afimmune Pharmaceutical
    • 2.6.1 Afimmune Pharmaceutical Details
    • 2.6.2 Afimmune Pharmaceutical Major Business
    • 2.6.3 Afimmune Pharmaceutical Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.6.4 Afimmune Pharmaceutical Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Afimmune Pharmaceutical Recent Developments and Future Plans
  • 2.7 Zucara Therapeutics
    • 2.7.1 Zucara Therapeutics Details
    • 2.7.2 Zucara Therapeutics Major Business
    • 2.7.3 Zucara Therapeutics Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.7.4 Zucara Therapeutics Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Zucara Therapeutics Recent Developments and Future Plans
  • 2.8 Novo Nordisk
    • 2.8.1 Novo Nordisk Details
    • 2.8.2 Novo Nordisk Major Business
    • 2.8.3 Novo Nordisk Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.8.4 Novo Nordisk Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Novo Nordisk Recent Developments and Future Plans
  • 2.9 Adocia
    • 2.9.1 Adocia Details
    • 2.9.2 Adocia Major Business
    • 2.9.3 Adocia Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.9.4 Adocia Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Adocia Recent Developments and Future Plans
  • 2.10 Pfizer Inc.
    • 2.10.1 Pfizer Inc. Details
    • 2.10.2 Pfizer Inc. Major Business
    • 2.10.3 Pfizer Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Product and Solutions
    • 2.10.4 Pfizer Inc. Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Pfizer Inc. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Severe Hypertriglyceridemia (SHTG) Therapeutics by Company Revenue
    • 3.2.2 Top 3 Severe Hypertriglyceridemia (SHTG) Therapeutics Players Market Share in 2022
    • 3.2.3 Top 6 Severe Hypertriglyceridemia (SHTG) Therapeutics Players Market Share in 2022
  • 3.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Market: Region Footprint
    • 3.3.2 Severe Hypertriglyceridemia (SHTG) Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Treatment Method

  • 4.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value and Market Share by Treatment Method (2018-2023)
  • 4.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Forecast by Treatment Method (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Treatment Method (2018-2029)
  • 6.2 North America Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 North America Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Country
    • 6.3.1 North America Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Treatment Method (2018-2029)
  • 7.2 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Application (2018-2029)
  • 7.3 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Country
    • 7.3.1 Europe Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.3 France Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Treatment Method (2018-2029)
  • 8.2 Asia-Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Region (2018-2029)
    • 8.3.2 China Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.5 India Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Treatment Method (2018-2029)
  • 9.2 South America Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Application (2018-2029)
  • 9.3 South America Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Country
    • 9.3.1 South America Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Treatment Method (2018-2029)
  • 10.2 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Severe Hypertriglyceridemia (SHTG) Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Severe Hypertriglyceridemia (SHTG) Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Drivers
  • 11.2 Severe Hypertriglyceridemia (SHTG) Therapeutics Market Restraints
  • 11.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Severe Hypertriglyceridemia (SHTG) Therapeutics Industry Chain
  • 12.2 Severe Hypertriglyceridemia (SHTG) Therapeutics Upstream Analysis
  • 12.3 Severe Hypertriglyceridemia (SHTG) Therapeutics Midstream Analysis
  • 12.4 Severe Hypertriglyceridemia (SHTG) Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Severe Hypertriglyceridemia (SHTG) Therapeutics. Industry analysis & Market Report on Severe Hypertriglyceridemia (SHTG) Therapeutics is a syndicated market report, published as Global Severe Hypertriglyceridemia (SHTG) Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Severe Hypertriglyceridemia (SHTG) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,784.00
    		4,176.00
    		5,568.00
    		3,250.32
    		4,875.48
    		6,500.64
    		547,508.40
    		821,262.60
    		1,095,016.80
    		290,197.20
    		435,295.80
    		580,394.40
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo